Kondrat'ev Iu Iu, Sadovnikova N V, Kuraeva T L, Shcherbacheva L N, Smirnova O M
Probl Endokrinol (Mosk). 1987 Mar-Apr;33(2):3-6.
The authors described the use of an enzyme-linked immunosorbent assay to determine islet cell surface antibodies (ICSA) in persons at high risk of developing insulin dependent diabetes (IDD) and different types of manifest disease. Among I degree healthy relatives of probands with IDD antibodies were detected in 16%. In disorder of the oral GTT (a small group) ICSA were found in 57% of examinees. In the group of IDD patients which was heterogeneous in duration of disease and age at its onset, the frequency of ICSA was 38%. The least frequency (10%) of antibodies was observed in patients with non-insulin dependent (NIDD) compensated by a diet and oral hypoglycaemic drugs. Among non-compensated NIDD patients 62% were ICSA-positive. Thus, ICSA determined by the enzyme-linked immunosorbent assay, could be employed as a marker of autoimmune damage of the insular apparatus for prognosis of the development of "primary" and "secondary" insulin dependence.
作者描述了使用酶联免疫吸附测定法来测定胰岛素依赖型糖尿病（IDD）高危人群及不同类型显性疾病患者的胰岛细胞表面抗体（ICSA）。在患有IDD先证者的I级健康亲属中，16%检测到抗体。在口服葡萄糖耐量试验异常者（一小部分人群）中，57%的受检者发现有ICSA。在疾病病程和发病年龄各异的IDD患者组中，ICSA的出现频率为38%。在通过饮食和口服降糖药得到控制的非胰岛素依赖型（NIDD）患者中，抗体出现频率最低（10%）。在未得到控制的NIDD患者中，62%为ICSA阳性。因此，通过酶联免疫吸附测定法测定的ICSA，可作为胰岛器官自身免疫损伤的标志物，用于预测“原发性”和“继发性”胰岛素依赖的发展。
